University of Pennsylvania Hospital Center
Welcome,         Profile    Billing    Logout  
 12 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avigan, David
NCT01067287: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Active, not recruiting
2
35
US, RoW
CT-011, Dendritic Cell Fusion Vaccine
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Rambam Health Care Campus, Gateway for Cancer Research, United States Department of Defense
Multiple Myeloma
09/24
12/24
NCT00799110: Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Active, not recruiting
2
23
US
GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, DC/tumor fusion vaccine, imiquimod
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
12/24
12/24
NCT06138275: Elranatamab in R/R Multiple Myeloma

Recruiting
2
32
US
Elranatamab
Massachusetts General Hospital, Pfizer
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
12/25
12/28
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
NCT00458536: Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Completed
1/2
38
US
Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Beth Israel Deaconess Medical Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute
Renal Cancer
12/14
07/23
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT02204085: A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1/2
33
US
GO-203-2c, GO-203-2c + Decitabine
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute
Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia
09/24
12/24
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active, not recruiting
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
12/23
12/24
NCT06518551: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting
1/2
49
US
Elotuzumab, BMS-901608, Iberdomide, CC-220, Iberdomide hydrochloride, C25H28N3O5Cl, BMS-986382, Dexamethasone, Decadron, 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Omar Nadeem, MD, Celgene, Bristol-Myers Squibb
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/34
NCT00697684: Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Completed
1
29
US
Antithymocyte Globulin, Clofarabine
Beth Israel Deaconess Medical Center, Genzyme, a Sanofi Company
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma
12/20
11/23
NCT06799026: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
25
US
Elranatamab, PF-06863135, Elranatamab-bcmm, Elrexfio, GM-CSF, Granulocyte-Macrophage Colony-Stimulating Factor, DC/MM Fusion Vaccine, Dendritic Cell/Tumor Fusion Vaccine
David Avigan, Pfizer
Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
09/28
09/30
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Available
N/A
US
DCVax-L
Northwest Biotherapeutics
GBM, Glioblastoma Multiforme
 
 
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Garfall, Alfred
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
NCT05932680: Limited-duration Teclistamab

Recruiting
2
75
US
Off Drug Surveillance
Abramson Cancer Center at Penn Medicine
Myeloma Multiple
06/25
01/27
NCT06056102: CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Recruiting
1
20
US
Cyclophosphamide, Cytoxan, CART-BCMA, Chimeric Antigen Receptor T cell (CART)/B cell maturation antigen (BCMA), huCART19, Chimeric Antigen Receptor T cell (CART)/ CD-19 Targeted Humanized CAR T Cell, Fludarabine, Fludara
National Institute of Allergy and Infectious Diseases (NIAID), University of Pennsylvania Clinical Cell and Vaccine Production Facility (CVPF)
Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
12/28
12/42
NCT03549442: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Active, not recruiting
1
40
US
BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
University of Pennsylvania, Novartis
Multiple Myeloma
03/36
03/36

Download Options